Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Complications of renal transplantation in children

Ruth A McDonald, MD
Section Editor
Patrick Niaudet, MD
Deputy Editor
Melanie S Kim, MD


Once the estimated glomerular filtration rate declines to less than 30 mL/min per 1.73 m2 (stage 4 chronic kidney disease), it is time to start preparing the child and the family for renal replacement therapy [1]. Although there have been many advances in conservative renal replacement therapy, renal transplantation is the best treatment for children with end-stage renal disease (ESRD) [2]. This was shown in a study from Australia and New Zealand, in which the risk for death was more than four times higher in children with ESRD treated with dialysis rather than renal transplantation [2]. Improvements in the care of young patients and advances in immunosuppressive therapy have also increased renal allograft and patient survival. Particularly, reduction in the frequency and severity of acute rejection has enhanced allograft survival [3].

This topic will provide an overview of the complications of renal transplantation in children. Some complications of renal transplantation are unique to children, while others are observed in all transplant recipients. Additional issues concerning transplantation in children and issues in renal transplantation common to both children and adults are presented elsewhere. (See "General principles of renal transplantation in children" and "Outcomes of renal transplantation in children".)


The causes of renal allograft dysfunction vary with the time after transplantation. These time periods are usually classified as immediate (zero to one week postsurgery), early (1 to 12 weeks postsurgery), late acute (after three months), and late chronic (years). (See "Evaluation and diagnosis of the patient with renal allograft dysfunction".)

Causes of delayed graft function (immediate renal failure persisting after transplantation) include postischemic acute kidney injury, vascular thrombosis of the renal artery or vein, urologic complications (ie, urinary leak or obstruction), and rarely, hyperacute rejection.

Among patients with initial graft function who develop early renal insufficiency (ie, 1 to 12 weeks post-transplantation), the major causes of graft dysfunction are acute allograft rejection, calcineurin inhibitor toxicity, urinary obstruction, infection, hypovolemia, and recurrent disease.

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Oct 2017. | This topic last updated: Jul 31, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.
  2. McDonald SP, Craig JC, Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease. N Engl J Med 2004; 350:2654.
  3. The North American Pediatric Renal Trials and Collaborative Studies 2014 Annual Report. Available at: https://web.emmes.com/study/ped/annlrept/annlrept.html (Accessed on October 02, 2015).
  4. Locke JE, Segev DL, Warren DS, et al. Outcomes of kidneys from donors after cardiac death: implications for allocation and preservation. Am J Transplant 2007; 7:1797.
  5. McDonald RA, Smith JM, Stablein D, Harmon WE. Pretransplant peritoneal dialysis and graft thrombosis following pediatric kidney transplantation: a NAPRTCS report. Pediatr Transplant 2003; 7:204.
  6. Smith JM, Stablein D, Singh A, et al. Decreased risk of renal allograft thrombosis associated with interleukin-2 receptor antagonists: a report of the NAPRTCS. Am J Transplant 2006; 6:585.
  7. Kranz B, Vester U, Nadalin S, et al. Outcome after kidney transplantation in children with thrombotic risk factors. Pediatr Transplant 2006; 10:788.
  8. Broyer M, Gagnadoux MF, Sierro A, et al. Preventive treatment of vascular thrombosis after kidney transplantation in children with low molecular weight heparin. Transplant Proc 1991; 23:1384.
  9. Kim MS, Stablein D, Harmon WE. Renal transplantation in children with congenital nephrotic syndrome: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1998; 2:305.
  10. Salvatierra O Jr, Millan M, Concepcion W. Pediatric renal transplantation with considerations for successful outcomes. Semin Pediatr Surg 2006; 15:208.
  11. Routh JC, Yu RN, Kozinn SI, et al. Urological complications and vesicoureteral reflux following pediatric kidney transplantation. J Urol 2013; 189:1071.
  12. Tavakoli A, Surange RS, Pearson RC, et al. Impact of stents on urological complications and health care expenditure in renal transplant recipients: results of a prospective, randomized clinical trial. J Urol 2007; 177:2260.
  13. Dharnidharka VR, Araya CE, Wadsworth CS, et al. Assessing the value of ureteral stent placement in pediatric kidney transplant recipients. Transplantation 2008; 85:986.
  14. Salmela KT, von Willebrand EO, Kyllönen LE, et al. Acute vascular rejection in renal transplantation--diagnosis and outcome. Transplantation 1992; 54:858.
  15. Grandtnerová B, Mäcková N, Hovoricová B, Jahnová E. Hyperacute rejection of living related kidney grafts caused by endothelial cell-specific antibodies: case reports. Transplant Proc 2008; 40:2422.
  16. Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 2004; 4:384.
  17. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11 Suppl 15:S1.
  18. Benfield MR, Herrin J, Feld L, et al. Safety of kidney biopsy in pediatric transplantation: a report of the Controlled Clinical Trials in Pediatric Transplantation Trial of Induction Therapy Study Group. Transplantation 1999; 67:544.
  19. Birk PE, Blydt-Hansen TD, Dart AB, et al. Low incidence of adverse events in outpatient pediatric renal allograft biopsies. Pediatr Transplant 2007; 11:196.
  20. Birk PE, Rush DN. Protocol biopsies should be standard of care for pediatric renal allograft recipients! Pediatr Transplant 2006; 10:760.
  21. Shapiro R, Starzl TE. Protocol biopsies should not (yet) be the standard of care in pediatric renal transplant recipients. Pediatr Transplant 2006; 10:766.
  22. Guyot C, Nguyen JM, Cochat P, et al. Risk factors for chronic rejection in pediatric renal allograft recipients. Pediatr Nephrol 1996; 10:723.
  23. Kasiske BL, Kalil RS, Lee HS, Rao KV. Histopathologic findings associated with a chronic, progressive decline in renal allograft function. Kidney Int 1991; 40:514.
  24. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44:411.
  25. Zarifian A, Meleg-Smith S, O'donovan R, et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999; 55:2457.
  26. Lin CC, King KL, Chao YW, et al. Tacrolimus-associated hemolytic uremic syndrome: a case analysis. J Nephrol 2003; 16:580.
  27. Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005; 5:2441.
  28. Feinstein S, Keich R, Becker-Cohen R, et al. Is noncompliance among adolescent renal transplant recipients inevitable? Pediatrics 2005; 115:969.
  29. Rianthavorn P, Ettenger RB. Medication non-adherence in the adolescent renal transplant recipient: a clinician's viewpoint. Pediatr Transplant 2005; 9:398.
  30. Smith JM, Ho PL, McDonald RA, North American Pediatric Renal Transplant Cooperative Study. Renal transplant outcomes in adolescents: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002; 6:493.
  31. Nevins TE, Thomas W. Quantitative patterns of azathioprine adherence after renal transplantation. Transplantation 2009; 87:711.
  32. Ettenger RB, Rosenthal JT, Marik JL, et al. Improved cadaveric renal transplant outcome in children. Pediatr Nephrol 1991; 5:137.
  33. Meyers KE, Thomson PD, Weiland H. Noncompliance in children and adolescents after renal transplantation. Transplantation 1996; 62:186.
  34. Schweizer RT, Rovelli M, Palmeri D, et al. Noncompliance in organ transplant recipients. Transplantation 1990; 49:374.
  35. Chisholm-Burns MA, Spivey CA, Rehfeld R, et al. Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. Am J Transplant 2009; 9:2497.
  36. Fine RN, Becker Y, De Geest S, et al. Nonadherence consensus conference summary report. Am J Transplant 2009; 9:35.
  37. Dew MA, Dabbs AD, Myaskovsky L, et al. Meta-analysis of medical regimen adherence outcomes in pediatric solid organ transplantation. Transplantation 2009; 88:736.
  38. Watson AR, Harden PN, Ferris ME, et al. Transition from pediatric to adult renal services: a consensus statement by the International Society of Nephrology (ISN) and the International Pediatric Nephrology Association (IPNA). Kidney Int 2011; 80:704.
  39. Bell LE, Bartosh SM, Davis CL, et al. Adolescent Transition to Adult Care in Solid Organ Transplantation: a consensus conference report. Am J Transplant 2008; 8:2230.
  40. Beck DE, Fennell RS, Yost RL, et al. Evaluation of an educational program on compliance with medication regimens in pediatric patients with renal transplants. J Pediatr 1980; 96:1094.
  41. Cameron JS. Recurrent primary disease and de novo nephritis following renal transplantation. Pediatr Nephrol 1991; 5:412.
  42. Cochat P, Fargue S, Mestrallet G, et al. Disease recurrence in paediatric renal transplantation. Pediatr Nephrol 2009; 24:2097.
  43. NAPRTCS: 2008 Annual Report, Rockville, MD, EMMES, 2008. Available at: https://web.emmes.com/study/ped/announce.htm (Accessed on November 09, 2008).
  44. Tejani A, Stablein DH. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 1992; 2:S258.
  45. Fine RN. Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol 2007; 22:496.
  46. Van Stralen KJ, Verrina E, Belingheri M, et al. Impact of graft loss among kidney diseases with a high risk of post-transplant recurrence in the paediatric population. Nephrol Dial Transplant 2013; 28:1031.
  47. Senggutuvan P, Cameron JS, Hartley RB, et al. Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol 1990; 4:21.
  48. Hickson LJ, Gera M, Amer H, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009; 87:1232.
  49. Habib R, Hebert D, Gagnadoux MF, Broyer M. Transplantation in idiopathic nephrosis. Transplant Proc 1982; 14:489.
  50. Pinto J, Lacerda G, Cameron JS, et al. Recurrence of focal segmental glomerulosclerosis in renal allografts. Transplantation 1981; 32:83.
  51. Weber S, Tönshoff B. Recurrence of focal-segmental glomerulosclerosis in children after renal transplantation: clinical and genetic aspects. Transplantation 2005; 80:S128.
  52. Ding WY, Koziell A, McCarthy HJ, et al. Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence. J Am Soc Nephrol 2014; 25:1342.
  53. Habib R, Antignac C, Hinglais N, et al. Glomerular lesions in the transplanted kidney in children. Am J Kidney Dis 1987; 10:198.
  54. Braun MC, Stablein DM, Hamiwka LA, et al. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience. J Am Soc Nephrol 2005; 16:2225.
  55. Little MA, Dupont P, Campbell E, et al. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int 2006; 69:504.
  56. Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 2003; 18:1095.
  57. Artz MA, Steenbergen EJ, Hoitsma AJ, et al. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation 2003; 76:821.
  58. Le Quintrec M, Zuber J, Moulin B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013; 13:663.
  59. Bobrowski AE, Langman CB. The primary hyperoxalurias. Semin Nephrol 2008; 28:152.
  60. Ruggiero B, Vivarelli M, Gianviti A, et al. Lupus nephritis in children and adolescents: results of the Italian Collaborative Study. Nephrol Dial Transplant 2013; 28:1487.
  61. Penn I. Renal transplantation for Wilms tumor: report of 20 cases. J Urol 1979; 122:793.
  62. Broyer M, Guest G, Gagnadoux MF, Beurton D. Hypertension following renal transplantation in children. Pediatr Nephrol 1987; 1:16.
  63. Sorof JM, Poffenbarger T, Portman R. Abnormal 24-hour blood pressure patterns in children after renal transplantation. Am J Kidney Dis 2000; 35:681.
  64. Baluarte HJ, Gruskin AB, Ingelfinger JR, et al. Analysis of hypertension in children post renal transplantation--a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Nephrol 1994; 8:570.
  65. Ingelfinger JA, Brewer ED. Pediatric post-transplant hypertension: a review of current standards of care. Child Nephrol Urol 1992; 12:139.
  66. Malekzadeh MH, Brennan LP, Payne VC Jr, Fine RN. Hypertension after renal transplantation in children. J Pediatr 1975; 86:370.
  67. Sorof JM, Sullivan EK, Tejani A, Portman RJ. Antihypertensive medication and renal allograft failure: a North American Pediatric Renal Transplant Cooperative Study report. J Am Soc Nephrol 1999; 10:1324.
  68. Curtis JJ. Hypertension after renal transplantation: cyclosporine increases the diagnostic and therapeutic considerations. Am J Kidney Dis 1989; 13:28.
  69. Luke RG. Pathophysiology and treatment of posttransplant hypertension. J Am Soc Nephrol 1991; 2:S37.
  70. Wilson AC, Greenbaum LA, Barletta GM, et al. High prevalence of the metabolic syndrome and associated left ventricular hypertrophy in pediatric renal transplant recipients. Pediatr Transplant 2010; 14:52.
  71. McMullin ND, Reidy JF, Koffman CG, et al. The management of renal transplant artery stenosis in children by percutaneous transluminal angioplasty. Transplantation 1992; 53:559.
  72. Parekh RS, Carroll CE, Wolfe RA, Port FK. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 2002; 141:191.
  73. Becker-Cohen R, Nir A, Rinat C, et al. Risk factors for cardiovascular disease in children and young adults after renal transplantation. Clin J Am Soc Nephrol 2006; 1:1284.
  74. Puliyanda DP, Stablein DM, Dharnidharka VR. Younger age and antibody induction increase the risk for infection in pediatric renal transplantation: a NAPRTCS report. Am J Transplant 2007; 7:662.
  75. Yin S, Powell EC, Trainor JL. Serious bacterial infections in febrile outpatient pediatric kidney transplant recipients. Pediatr Infect Dis J 2011; 30:136.
  76. Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med 1990; 89:255.
  77. Silva A, Rodig N, Passerotti CP, et al. Risk factors for urinary tract infection after renal transplantation and its impact on graft function in children and young adults. J Urol 2010; 184:1462.
  78. Dharnidharka VR, Agodoa LY, Abbott KC. Effects of urinary tract infection on outcomes after renal transplantation in children. Clin J Am Soc Nephrol 2007; 2:100.
  79. Esezobor CI, Nourse P, Gajjar P. Urinary tract infection following kidney transplantation: frequency, risk factors and graft function. Pediatr Nephrol 2012; 27:651.
  80. Höcker B, Zencke S, Krupka K, et al. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir. Transplantation 2016; 100:862.
  81. Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics 1992; 90:216.
  82. Broyer M, Tete MJ, Guest G, et al. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 1997; 99:35.
  83. Zamora I, Simon JM, Da Silva ME, Piqueras AI. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 1994; 8:190.
  84. Danerseau AM, Robinson JL. Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs. World J Pediatr 2008; 4:254.
  85. Chaves Tdo S, Lopes MH, de Souza VA, et al. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients. Pediatr Transplant 2005; 9:192.
  86. Höcker B, Fickenscher H, Delecluse HJ, et al. Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study. Clin Infect Dis 2013; 56:84.
  87. McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8:984.
  88. Smith JM, Corey L, Healey PJ, et al. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Transplantation 2007; 83:1423.
  89. Smith JM, McDonald RA, Finn LS, et al. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant 2004; 4:2109.
  90. Herman J, Van Ranst M, Snoeck R, et al. Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique. Pediatr Transplant 2004; 8:485.
  91. Haysom L, Rosenberg AR, Kainer G, et al. BK viral infection in an Australian pediatric renal transplant population. Pediatr Transplant 2004; 8:480.
  92. Müller A, Beck B, Theilemann K, et al. Detection of polyomavirus BK and JC in children with kidney diseases and renal transplant recipients. Pediatr Infect Dis J 2005; 24:778.
  93. Smith JM, Dharnidharka VR, Talley L, et al. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2007; 2:1037.
  94. Thomas A, Dropulic LK, Rahman MH, Geetha D. Ureteral stents: a novel risk factor for polyomavirus nephropathy. Transplantation 2007; 84:433.
  95. Hymes LC, Warshaw BL. Polyomavirus (BK) in pediatric renal transplants: evaluation of viremic patients with and without BK associated nephritis. Pediatr Transplant 2006; 10:920.
  96. Ginevri F, Azzi A, Hirsch HH, et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7:2727.
  97. Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant 2008; 8:9.
  98. Coutinho HM, Groothoff JW, Offringa M, et al. De novo malignancy after paediatric renal replacement therapy. Arch Dis Child 2001; 85:478.
  99. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2013 Annual Data Report: kidney. Am J Transplant 2015; 15 Suppl 2:1.
  100. Smith JM, Martz K, McDonald RA, Harmon WE. Solid tumors following kidney transplantation in children. Pediatr Transplant 2013; 17:726.
  101. Debray D, Baudouin V, Lacaille F, et al. De novo malignancy after solid organ transplantation in children. Transplant Proc 2009; 41:674.
  102. Dharnidharka VR, Martz KL, Stablein DM, Benfield MR. Improved survival with recent Post-Transplant Lymphoproliferative Disorder (PTLD) in children with kidney transplants. Am J Transplant 2011; 11:751.
  103. Holmberg C, Jalanko H. Long-term effects of paediatric kidney transplantation. Nat Rev Nephrol 2016; 12:301.
  104. Soergel TM, Cain MP, Misseri R, et al. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol 2004; 172:1649.
  105. Castellan M, Gosalbez R, Perez-Brayfield M, et al. Tumor in bladder reservoir after gastrocystoplasty. J Urol 2007; 178:1771.
  106. Robert JJ, Tete MJ, Crosnier H, Broyer M. [Sugar diabetes after renal transplantation in children]. Ann Pediatr (Paris) 1993; 40:112.
  107. Al-Uzri A, Stablein DM, A Cohn R. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 72:1020.
  108. Burroughs TE, Swindle JP, Salvalaggio PR, et al. Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. Transplantation 2009; 88:367.
  109. Robert JJ, Tête MJ, Guest G, et al. Diabetes mellitus in patients with infantile cystinosis after renal transplantation. Pediatr Nephrol 1999; 13:524.
  110. Haffner D, Schüler U. Metabolic bone disease after renal transplantation. Curr Opin Pediatr 2014; 26:198.
  111. Yorgin PD, Belson A, Sanchez J, et al. Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. Am J Kidney Dis 2002; 40:1306.
  112. Krischock LA, van Stralen KJ, Verrina E, et al. Anemia in children following renal transplantation-results from the ESPN/ERA-EDTA Registry. Pediatr Nephrol 2016; 31:325.
  113. Pinto V, Grandy J, Zambrano P, et al. Severe anemia from parvovirus b19 infection in pediatric renal transplant recipients: two case reports. Transplant Proc 2008; 40:3261.
  114. Irtan S, Maisin A, Baudouin V, et al. Renal transplantation in children: critical analysis of age related surgical complications. Pediatr Transplant 2010; 14:512.
  115. Smith KM, Windsperger A, Alanee S, et al. Risk factors and treatment success for ureteral obstruction after pediatric renal transplantation. J Urol 2010; 183:317.
  116. Ranchin B, Chapuis F, Dawhara M, et al. Vesicoureteral reflux after kidney transplantation in children. Nephrol Dial Transplant 2000; 15:1852.
  117. Giuliani S, Gamba P, Kiblawi R, et al. Lymphocele after pediatric kidney transplantation: incidence and risk factors. Pediatr Transplant 2014; 18:720.